GRI Bio
4 hedge funds and large institutions have $82.8K invested in GRI Bio in 2023 Q4 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, 0 reducing their positions, and 1 closing their positions.
300% more funds holding
Funds holding: 1 → 4 (+3)
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
12% less ownership
Funds ownership: 19.34% → 7.34% (-12%)
74% less capital inflows, than outflows
Capital inflows: $209K | Capital outflows: $808K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$83.4K |
| 2 |
HRT Financial
New York
|
+$41.7K |
| 3 |
Renaissance Technologies
New York
|
+$41.7K |
| 4 |
Stratos Wealth Partners
Beachwood,
Ohio
|
+$41.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
-$808K |
GRI Hedge Fund Activity: Q4 2023 in Review
4 of the 6,877 institutional investors tracked by Wall St. Rank reported a position in GRI Bio (GRI) for Q4 2023, worth a combined $82.8K — down 91% from $887K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new GRI positions and 1 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $83.4K. The largest seller was Altium Capital Management, exiting entirely with an estimated $808K sold.
- 4 institutional investors held GRI Bio (GRI) as of Q4 2023, up from 1 in Q3 2023.
- Funds reported $82.8K of GRI Bio stock for Q4 2023, down 91% quarter-over-quarter.
- 4 funds opened new GRI Bio positions in Q4 2023 and 1 closed out, a net change of +3 holders.
- The largest GRI Bio buyer in Q4 2023 was Citadel Advisors, an estimated $83.4K added.
- The largest GRI Bio seller in Q4 2023 was Altium Capital Management, an estimated $808K sold.
Based on aggregated 13F filings for Q4 2023.